Skip to main content
TipRanks
Go Ultimate75% OFF

Beauty Health (V7A) Q3 2026 Earnings Report

1 Followers

DE:V7A Q3 2026 EPS Results

Actual EPS
-EUR 0.13
Consensus EPS
-EUR 1.21
Beat/Miss
Beat by +EUR 1.08
One Year Ago EPS
-EUR 1.63

DE:V7A Q3 2026 Revenue Results

Actual Revenue
EUR 62.53M
Expected Revenue
EUR 61.44M
Beat/Miss
Beat by +EUR 1.09M
YoY Revenue Growth
-2.10%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
DE:V7A Upcoming Earnings

Beauty Health's next earnings date is estimated for March 17, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:V7A Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:71.45%|
Earnings Call Sentiment|Positive

The call was predominantly positive. Revenue stabilization, the return of consumables growth, stronger gross margins, positive GAAP operating income, approximately 50% adjusted EBITDA growth, strong free cash flow, debt retirement and higher adjusted EBITDA guidance significantly outweighed the challenges. However, equipment sales, utilization, EMEA and APAC performance remain pressured, and fourth-quarter margins and operating expenses are expected to move unfavorably.

Company Guidance

For full year 2026, SkinHealth Systems now expects net sales of $281 million-$287 million, compared with its previous guidance of $280 million-$290 million, and adjusted EBITDA of $48 million-$50 million, compared with its previous guidance of $39 million-$46 million. Fourth quarter assumptions reflect continued pressure on equipment and further work to improve EMEA revenue performance; adjusted gross margin is expected to moderate sequentially as equipment represents a greater percentage of the mix and the one-time tariff benefit does not repeat, while operating expenses are projected to increase quarter-over-quarter, including research and development expenses that are projected to increase meaningfully from the third quarter as a number of the company’s 2027 and 2028 projects begin to ramp. The company is targeting a planned introduction of another complementary device in 2027, and the next-generation Hydrafacial platform is currently targeted for 2028.

  • Revenue Decline ModeratedThird-quarter revenue was $69.2 million, toward the upper end of the $65 million-$70 million guidance range. Revenue declined 2.1% year-over-year, improving from declines of 7.8% in the second quarter and 6.7% in the first quarter.
  • Consumables Returned to GrowthGlobal consumables revenue increased 1.2% year-over-year to $50.4 million, representing approximately 73% of total revenue. Growth was supported by stronger signature consumables performance, the HydraScalp relaunch, HydraClear, and other commercial initiatives.
  • Improved Profitability and Adjusted EBITDAGAAP gross margin was 68.2%, compared with 64.6% in the prior-year period. Adjusted gross margin was 71.8%, up from 68% and representing an improvement of approximately 380 basis points. Adjusted EBITDA was $13.4 million, or 19.3% of revenue, compared with $8.9 million, or 12.6%, an increase of approximately 50%.
  • Positive GAAP Operating IncomeGAAP operating income was approximately $5 million, compared with an operating loss of $6.2 million in the prior-year quarter. This was the second consecutive quarter with positive GAAP operating income. Net loss was approximately $0.9 million.
  • Cost Management and Operating EfficiencyGAAP operating expenses declined to approximately $42.2 million from $51.9 million, while adjusted operating expenses declined to approximately $36.3 million from $39.1 million. Management cited lower professional fees, lower commissions, APAC go-to-market changes, improved inventory management, lower excess and obsolete charges, and a more efficient operating model.
  • Americas GrowthAmericas net sales increased 1.4% year-over-year to $48.9 million, with consumables revenue up 4.3% according to the prepared remarks and 4.2% in the Q&A. Management attributed the performance to commercial execution, sales-force retraining, marketing resegmentation and remessaging, stronger signature consumables, HydraScalp, HydraClear, and non-medical channels.
  • Installed Base ExpansionGlobal active systems increased to 37,342 at the end of the third quarter. Management said the company continues to grow its footprint and provider reach each quarter.
  • Improving System Retention SignalsThe company reported net churn of 59 units, primarily driven by the Americas, where there was a lower fall-off of devices and some consumers repurchased systems that had previously been dormant. Management said outreach to past dormant accounts was producing some reactivation.
  • Hydrafacial Commercial and Provider InitiativesThe company strengthened commercial leadership and accountability, invested in training, processes and selling tools, adopted more targeted customer segmentation and value-based selling, expanded corporate and multi-location account relationships, and launched the Hydrafacial Impact program to help providers attract customers, increase repeat visits, improve treatment economics and raise utilization.
  • U.S. Rental Program LaunchThe company introduced a U.S. rental program during the quarter to address the upfront capital investment barrier for qualified providers. Management is evaluating lead quality, conversion, provider adoption and treatment activity after placement, with the expectation that the program will build contribution over time as it scales.
  • Product and Treatment InnovationThe company introduced the HydraGlow Pre-Extraction Peel and Hydralock HA Biocellulose Mask in September and launched the HydraClear booster in October. In clinical evaluation, a series of HydraClear treatments produced a 38% mean reduction in total blemishes. The company also relaunched HydraScalp and Keravive to expand use of existing Hydrafacial systems into scalp and hair-health treatments.
  • SkinStylus Growth and European ExpansionSkinStylus consumables grew 39% year-over-year in the quarter. The company expanded SkinStylus into six key European markets using its existing international commercial infrastructure.
  • Broader Product PipelineThe company is progressing toward a planned introduction of another complementary device in 2027 and is advancing a next-generation Hydrafacial platform targeted for 2028, intended to improve clinical outcomes, provider workflow and treatment experience.
  • Strong Cash Flow and Debt RetirementCash flow from operations was approximately $11.3 million, capital expenditures were approximately $1.1 million, and free cash flow was approximately $10.2 million. On September 30, the company repaid the remaining $103.2 million principal amount of its 1.25% convertible senior notes due in 2026, plus approximately $645,000 of accrued and unpaid interest.
  • Liquidity PositionThe company ended the quarter with approximately $112.4 million in cash and cash equivalents and said its liquidity position provides sufficient flexibility to operate and invest in the business. Approximately $250 million of convertible debt remains, maturing in the fourth quarter of 2028.
  • Raised Adjusted EBITDA GuidanceFull-year 2026 adjusted EBITDA guidance was increased to $48 million-$50 million from $39 million-$46 million.
  • Maintained Revenue Guidance RangeFull-year 2026 net sales guidance was updated to $281 million-$287 million, compared with the previous guidance of $280 million-$290 million.

DE:V7A Earnings History

DE:V7A earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 17, 20272026 (Q4)-0.41--1.08――
Nov 05, 20262026 (Q3)-1.21-0.13-1.6392.22% (+1.50)
Aug 06, 20262026 (Q2)-0.45-0.362.89-112.50% (-3.25)
May 07, 20262026 (Q1)-1.34-0.90-1.4537.50% (+0.54)
Mar 12, 20262025 (Q4)-0.88-1.08-1.4525.00% (+0.36)
Nov 06, 20252025 (Q3)-1.34-1.63-2.7140.00% (+1.08)
Aug 07, 20252025 (Q2)-0.962.89-1.03380.70% (+3.92)
May 08, 20252025 (Q1)-2.32-1.45-0.18-700.00% (-1.27)
Mar 12, 20252024 (Q4)-2.06-1.45-0.51-185.20% (-0.94)
Nov 12, 20242024 (Q3)-1.67-2.71-9.0469.99% (+6.32)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed